Literature DB >> 19770436

Vorinostat for the treatment of bullous pemphigoid in the setting of advanced, refractory cutaneous T-cell lymphoma.

Jennifer M Gardner1, Katherine G Evans, Steven Goldstein, Ellen J Kim, Carmela C Vittorio, Alain H Rook.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19770436     DOI： 10.1001/archdermatol.2009.229

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN： 0003-987X


× No keyword cloud information.
  4 in total

1.  Cleavage isn't everything: potential novel mechanisms of exfoliative toxin-mediated blistering.

Authors:  Takeru Funakoshi; Aimee S Payne
Journal:  Am J Pathol       Date:  2010-11-05       Impact factor: 4.307

2.  The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients.

Authors:  Michael J Kelly-Sell; Youn H Kim; Suzanne Straus; Bernice Benoit; Cameron Harrison; Katherine Sutherland; Randall Armstrong; Wen-Kai Weng; Louise C Showe; Maria Wysocka; Alain H Rook
Journal:  Am J Hematol       Date:  2012-02-24       Impact factor: 10.047

3.  Inhibition of cell-mediated immunity by the histone deacetylase inhibitor vorinostat: implications for therapy of cutaneous T-cell lymphoma.

Authors:  Sasha Stephen; Kelly A Morrissey; Bernice M Benoit; Ellen J Kim; Carmela C Vittorio; Sunita D Nasta; Louise C Showe; Maria Wysocka; Alain H Rook
Journal:  Am J Hematol       Date:  2011-12-21       Impact factor: 10.047

4.  A rare association of bullous pemphigoid with mycosis fungoides and Sézary syndrome.

Authors:  Andjela Egger; Najy Issa; Robert S Kirsner; Paolo Romanelli; Naiem Tony Issa
Journal:  JAAD Case Rep       Date:  2020-05-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.